B&L Eyes Zyoptix Per-Procedure Fees To Recoup LASIK Royalties To Visx
This article was originally published in The Gray Sheet
Executive Summary
Bausch & Lomb will look to its Zyoptix eye diagnostic system to eventually offset royalty payments to LASIK competitor Visx.
You may also be interested in...
B&L Looks To Zyoptix, Eyetracking System to Boost Refractive Market Share
Bausch & Lomb will incorporate its Active Eyetracking high-speed image processing system into all Technolas 217A excimer lasers sold after November at no additional cost.
B&L Looks To Zyoptix, Eyetracking System to Boost Refractive Market Share
Bausch & Lomb will incorporate its Active Eyetracking high-speed image processing system into all Technolas 217A excimer lasers sold after November at no additional cost.
Applied Biosystems' Good Genes Boost Stock 56% In 2000; Index Ahead 29%
The untapped possibilities of genetic analysis for early stage detection of disease combined with a nearly completed effort to map the human genome helped breathe new life into the diagnostics sector in 2000, led by Applera Corp. (formerly PE Corp.) and its two component business units, Applied Biosystems and Celera Genomics.